Navigation Links
Lupin Expands US Pediatric Brands Portfolio

MUMBAI, India and BALTIMORE, September 23, 2013 /PRNewswire/ --

Pharmaceutical Major, Lupin Ltd. and its US subsidiary, Lupin Pharmaceuticals Inc. (collectively Lupin) announced today that it has signed a strategic co-promotion agreement with US based Onset Dermatologics, LLC ("Onset") that grants Lupin exclusive rights to promote Onset's Locoid® Lotion (hydrocortisone butyrate 0.1%) to Pediatricians in the US. Locoid® is the most highly prescribed mid-potency steroid brand in the U.S.

Locoid® Lotion is a corticosteroid indicated for the topical treatment of mild to moderate Atopic Dermatitis in patients 3 months of age and older. Atopic Dermatitis (AD) is one of the most common skin disorders in young children and has a prevalence of 10% to 20% in the first decade of life. It is a chronic illness that requires a multifaceted treatment strategy in the setting of limited therapeutic options. Between 1997 and 2004, pediatric patients with AD (newborn to 18 years of age) accounted for an estimated 7.4 million office visits in the United States alone. AD, more commonly called eczema, now affects 10 to 20 percent of children in the United States and direct health-care costs exceed $3 billion, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Locoid® Lotion currently participates in a market that includes 17% of school-age children in the US between the ages of 5 - 7 years which is about 9.2 million children.

The addition of Locoid® Lotion will enable Lupin to strengthen its US Brand business and expand its product portfolio for the US Pediatrics segment. Lupin's current pediatric portfolio consists of Suprax® and Alinia® for Oral Suspension and such the Company is well positioned to capitalize on this opportunity. Onset has had minimal promotion of Locoid® Lotion to pediatricians. Lupin's 160+ strong specialty sales force will promote Locoid® Lotion with Onset providing strategic marketing support thus creating an opportunity for incremental revenues with minimal additional sales or marketing expenses.

"We are very pleased with the addition of Locoid® Lotion to our Brand portfolio and are committed to bring meaningful products to the US Pediatric community." said Vinita Gupta, CEO, Lupin Pharmaceuticals Inc. and Lupin Limited. Bob Moccia, President of Onset Dermatologics said, "This partnership will give pediatricians greater opportunity to utilize Locoid® lotion in their patients while Onset maintains its focus on promoting Locoid® to the dermatology community.  We are confident that Locoid® will continue to be the most prescribed mid-potency steroid brand in the U.S."

About Onset Dermatologics

Headquartered in Cumberland RI, Onset Dermatologics is a fully-integrated prescription dermatology company with a mission to deliver innovative therapies to dermatologists and their patients. In addition to Aurstat® Anti-Itch Hydrogel, Onset Dermatologics markets the prescription brands Locoid®, HylatopicPlus®, Tretin-X®, Minocin®, and Clarifoam®EF to dermatologists and their allied healthcare providers. Onset is expanding rapidly through internally generated innovation, acquisitions, in-licensing, and co-marketing opportunities. For additional information, visit

About Lupin Limited

Headquartered in Mumbai, Lupin is an innovation led transnational pharmaceutical company producing and developing a wide range of branded and generic formulations and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership positions in the Anti-TB and Cephalosporin segment.

Lupin is the 5th largest and fastest growing top 5 generics player in the US (5.3% market share by prescriptions, IMS Health) and the 3rd largest Indian pharmaceutical company by sales. The Company is also the fastest growing top 10 generic pharmaceutical players in Japan and South Africa (IMS).

For the financial year ended March 2013, Lupin's Consolidated turnover and Profit after Tax were Rs. 94,616 million (USD 1.74 billion) and Rs. 13,142 million (USD 242 million) respectively. Please visit for more information.

Lupin Pharmaceuticals, Inc. is the wholly owned U.S. subsidiary of Lupin Limited.  Headquartered in Baltimore, Maryland, Lupin Pharmaceuticals, Inc. is dedicated to delivering high-quality, affordable generic medicines and branded formulations trusted by healthcare professionals and patients across geographies. For more information, visit

For further information or queries please contact -
Shamsher Gorawara
Head - Corporate Communications
Lupin Limited
Ph: +91-98-20-338-555

Safe Harbor Statement

SOURCE Lupin Ltd
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Lupin Limited: Quarter III Results, FY 2012-13
2. Building on a Legacy: Vinita Gupta, CEO of Lupin Pharmaceuticals, Inc., Named Ernst & Young U.S. 2012 Family Business Award of Excellence winner
3. SeraCare Life Sciences Expands R&D Facilities
4. Sam Solakyan Successfully Expands Vital Imaging Across California
5. American Cancer Society Expands Efforts to Reduce Burden of Cancer in Underserved Communities
6. SottoPelle expands its East Coast Presence
7. UBM Medica US Expands Network to Include Pharmacology and Psychopharmacology
8. Kush Bottles Expands Free and Same Day Delivery to Encompass More of Washington State
9. Sentry Data Systems Expands Support Organization To Address Pharmacy Procurement Management And Compliance Needs
10. Hill-Rom Holdings, Inc. Expands Stock Repurchase Authorization and Announces Fourth Quarter 2013 Dividend
11. RainTree Oncology Expands Management As Strategic Vision For Community Oncology Unfolds
Post Your Comments:
(Date:6/24/2016)... , June 24, 2016  Consumers have ... and regulators/payers have placed more emphasis on patient ... patient support programs in the pharmaceutical industry have ... medications. Consequently, pharmaceutical companies are focusing on becoming ... are providing products and services that improve health. ...
(Date:6/24/2016)... CAMBRIDGE, Mass. , June 24, 2016 /PRNewswire/ ... the Spaulding Rehabilitation Network,s Dean Center for ... of Physical Medicine and Rehabilitation, MIT Hacking Medicine, ... Center for Innovation, today announced the five finalists ... Hackathon for Lyme disease.  More than 100 scientists, ...
(Date:6/24/2016)... -- The Academy of Managed Care Pharmacy (AMCP) today ... allow biopharmaceutical companies to more easily share health care ... coverage decisions, a move that addresses the growing need ... The recommendations address restrictions in the sharing of product ... a prohibition that hinders decision makers from accessing HCEI ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice ... "Film editors can give their videos a whole new perspective by using the ... of Pixel Film Studios. , ProSlice Levels contains over 30 Different presets to ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes ... important health care topics including advance care planning, healthcare costs and patient and ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from reveals that behind the tendency ...
(Date:6/24/2016)... PASADENA, CA (PRWEB) , ... June 24, 2016 , ... Marcy was in a crisis. ... he would lash out at his family verbally and physically. , “When something upset him, ... table, he would use it. He would throw rocks at my other children and say ...
Breaking Medicine News(10 mins):